Oramed Pharmaceuticals Announces the Expansion of Its Scientific Board With a Prominent American Figure in Diabetes Research



    JERUSALEM, Israel, Jan. 31 /CNW/ -- Oramed Pharmaceuticals (OTC Bulletin
Board: ORMP; Frankfurt: OJU) has added the accomplished Derek LeRoith, MD PhD
to its world class scientific board.  With contributions leading to over 500
publications, Dr. LeRoith is presently the Chief of the Division of
Endocrinology and Diabetes in the Department of Medicine at the Mt. Sinai
School of Medicine.
    Dr. LeRoith began his studies in Cape Town, where he received both his
medical degree and completed his thesis for his PhD.  His career in America
started as the Chief of the Diabetes Branch at the National Institute of
Diabetes, Digestive and Kidney Diseases in the National Institute of Health in
Maryland, and he is now serving as the Chief of the Division of Endocrinology,
Diabetes and Bone Diseases.  He is a prominent member in over 15 professional
societies globally, including the Society for Endocrinology, Metabolism and
Diabetes of South Africa, the European Association for the Study of Diabetes,
and the American Diabetes Association.
    Dr. LeRoith has been granted a number of prominent administrative
responsibilities, including positions within the American Diabetes Association
(President of the Montgomery Chapter, President of the Washington D.C.
Affiliate, the Board of Directors, Chairperson of the Research and Grant
Panel), Chief of the Endocrine Consulting Services at the Clinical Center of
the National Institution of Health, President of the International Society for
Insulin-like Growth Factor Research, and Board of Directors for the Endocrine
Fellows Foundation, among many others.  His awards include, but are not
limited to, Medal for Physiology, the Bronte Stewart Award for PhD Thesis,
British Endocrine Society Transatlantic Medal, and multiple Memorial Lectures.
    CEO Nadav Kidron states, "We are proud to have Dr. Derek LeRoith join our
board of directors with his vast experience amongst the influential leaders in
diabetic research in the United States."  As our studies progress, this will
enable Oramed Pharmaceuticals, Inc. to open doors and expand the knowledge of
our technology into international territory.

    
    About Oramed Pharmaceuticals, Inc:
    
    Oramed Pharmaceuticals Inc. is an Israeli based company focused on the
development of oral delivery solutions based on proprietary technology.
Diabetes is one of the most rapidly growing diseases in the world and is one
that requires constant and often unpleasant monitoring and drug therapy
regimen.  Oramed is currently developing an orally soft gel insulin capsule
for the treatment of diabetes.  The Company is also pursuing the development
of oral delivery solutions for other drugs and vaccines.
    For more information on Oramed Pharmaceuticals please visit our website:
www.oramedpharma.com

    
    Investor Relations Contact:
    Oramed Pharmaceuticals, Inc.
    Vinisha Agnihotri(646) 467-2252
    info@oramedpharma.com
    www.oramedpharma.com

    




For further information:

For further information: Investor Relations, Vinisha Agnihotri, of
Oramed  Pharmaceuticals, Inc., +1-646-467-2252, or info@oramedpharma.com Web
Site: http://www.oramedpharma.com

Organization Profile

ORAMED PHARMACEUTICAL, INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890